These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19139300)

  • 1. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA; Lopresti BJ; Venneti S; Price J; Klunk WE; DeKosky ST; Mathis CA
    Arch Neurol; 2009 Jan; 66(1):60-7. PubMed ID: 19139300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study.
    Okello A; Edison P; Archer HA; Turkheimer FE; Kennedy J; Bullock R; Walker Z; Kennedy A; Fox N; Rossor M; Brooks DJ
    Neurology; 2009 Jan; 72(1):56-62. PubMed ID: 19122031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Fan Z; Brooks DJ; Okello A; Edison P
    Brain; 2017 Mar; 140(3):792-803. PubMed ID: 28122877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.
    Raji CA; Becker JT; Tsopelas ND; Price JC; Mathis CA; Saxton JA; Lopresti BJ; Hoge JA; Ziolko SK; DeKosky ST; Klunk WE
    J Neurosci Methods; 2008 Jul; 172(2):277-82. PubMed ID: 18582948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
    Okello A; Koivunen J; Edison P; Archer HA; Turkheimer FE; Någren K; Bullock R; Walker Z; Kennedy A; Fox NC; Rossor MN; Rinne JO; Brooks DJ
    Neurology; 2009 Sep; 73(10):754-60. PubMed ID: 19587325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Parbo P; Ismail R; Hansen KV; Amidi A; Mårup FH; Gottrup H; Brændgaard H; Eriksson BO; Eskildsen SF; Lund TE; Tietze A; Edison P; Pavese N; Stokholm MG; Borghammer P; Hinz R; Aanerud J; Brooks DJ
    Brain; 2017 Jul; 140(7):2002-2011. PubMed ID: 28575151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.
    Edison P; Archer HA; Gerhard A; Hinz R; Pavese N; Turkheimer FE; Hammers A; Tai YF; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurobiol Dis; 2008 Dec; 32(3):412-9. PubMed ID: 18786637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
    Klunk WE
    Arch Neurol; 2008 Oct; 65(10):1281-3. PubMed ID: 18852340
    [No Abstract]   [Full Text] [Related]  

  • 15. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
    Grimmer T; Riemenschneider M; Förstl H; Henriksen G; Klunk WE; Mathis CA; Shiga T; Wester HJ; Kurz A; Drzezga A
    Biol Psychiatry; 2009 Jun; 65(11):927-34. PubMed ID: 19268916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.
    Chételat G; Villemagne VL; Bourgeat P; Pike KE; Jones G; Ames D; Ellis KA; Szoeke C; Martins RN; O'Keefe GJ; Salvado O; Masters CL; Rowe CC;
    Ann Neurol; 2010 Mar; 67(3):317-24. PubMed ID: 20373343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.
    Verhoeff NP; Wilson AA; Takeshita S; Trop L; Hussey D; Singh K; Kung HF; Kung MP; Houle S
    Am J Geriatr Psychiatry; 2004; 12(6):584-95. PubMed ID: 15545326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.